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Copper (Cu) and cholesterol (Cho) are both associatedwith neurodegenerative illnesses in humans and animalsmodels.We studied
the effect in Wistar rats of oral supplementation with trace amounts of Cu (3 ppm) and/or Cho (2%) in drinking water for 2
months. Increased amounts of nonceruloplasmin-bound Cu were observed in plasma and brain hippocampus together with a
higher concentration of ceruloplasmin in plasma, cortex, and hippocampus. Cu, Cho, and the combined treatment Cu + Cho were
able to induce a higher Cho/phospholipid ratio in mitochondrial membranes with a simultaneous decrease in glutathione content.
The concentration of cardiolipin decreased and that of peroxidation products, conjugated dienes and lipoperoxides, increased.
Treatments including Cho produced rigidization in both the outer and inner mitochondrial membranes with a simultaneous
increase in permeability. No significant increase in Cyt C leakage to the cytosol was observed except in the case of cortex from rats
treated with Cu and Cho nor were there any significant changes in caspase-3 activity and the Bax/Bcl2 ratio. However, the A𝛽(1–
42)/(1–40) ratio was higher in cortex and hippocampus. These findings suggest an incipient neurodegenerative process induced by
Cu or Cho that might be potentiated by the association of the two supplements.
1. Introduction
It is well known that copper (Cu) is an essential transition
metal for all living organisms, functioning as cofactor for
many enzymes [1–3]. However, we and other laboratories
have demonstrated in vivo and in vitro that excess inorganic
Cu produces increased levels of reactive oxygen species
(ROS) and damage to biomolecules, ultimately promoting
cell death [4–7]. Humans are continuously at risk from
excess Cu due to involuntary exposure to pollution (contami-
nated water, food), professional activities [8–10], ingestion of
dietary supplements [10–12], and prolonged use of intrauter-
ine devices [13, 14]. Elevated Cu plasma levels, especially
of free-Cu or the so-called nonceruloplasmin-bound Cu
(NCBC), have been associated with neurodegenerative dam-
age [10, 15, 16]. In recent years, there has been a considerable
increase in the number of published papers relating Cu
to the neurodegenerative process [15–18]. In line with this,
Brewer [10] hypothesized that ingestion of inorganic Cu from
different sources is at least a partial cause ofAlzheimer disease
(AD) in developed countries. Squitti et al. [17–19] reported
that NCBC, which is loosely bound to molecules such as
serum albumin and other proteins, is one of the main risk
factors involved in AD development. They suggest that it
is the ratio of CP to Cu that is the crucial biomarker for
interpreting Cu-associated features in live AD patients.
AD has multiple conditioning and causative factors.
However, it was reported that inorganic Cu in conjunction
with a high fat diet sets the stage for the development of AD,
particularly if other risk factors are present [19]. Pappolla et
al. [20] proposed that hypercholesterolemia accelerates the
biochemical neuropathologic damage observed in transgenic
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mice. In addition, Notkola et al. [21] found that plasma
cholesterol (Cho) levels were predictors of AD prevalence in
a population-based sample of 444 men (aged 70–89 years).
More recently, in vivo models of AD-like neurodegenerative
diseases demonstrated that the association of Cu and Cho
increases the risk of the development of neurodegenerative
damage [22–24].
Cu overload has been extensively associated with ROS
overproduction in vitro and in vivo [6, 7, 25]. Oxidative stress
is considered a primary event in the development of AD [26].
Pope et al. [27] reported that ROS overproduction due to
the dysfunction of the electron transport chain is causative
of neurodegeneration associated with AD and Parkinson’s
disease.Moreover, some experimental evidence indicates that
alterations in mitochondrial energetics occur along with the
accumulation of oxidative damage before the cardinal signs
of AD pathogenesis in the brains of transgenic animalmodels
and human patients [28, 29].
As reviewed by Paradies et al. [30], the mitochondrion
is considered the most important cellular organelle con-
tributing to the neurodegenerative process, mainly through
respiratory chain dysfunction and the formation of reactive
oxygen species. Factors that increase the rate of mitochon-
drial ROS production lead to mitochondrial dysfunction
because of the oxidative-induced damage caused to vari-
ous crucial biomolecules such as mtDNA, lipids, and pro-
teins, thus increasing mitochondrial deterioration in a self-
perpetuating process [31]. Together with ROS accumulation,
mitochondrial dysfunction is one of the earliest and most
prominent features of AD [27, 28] and this condition is
strongly associated with multiple negative consequences.
Dysfunctional mitochondria generate high levels of ROS that
are ultimately toxic to cells, particularly those with a long
lifespan and low antioxidant defense system such as neurons
[28, 29]. At the same time,mitochondria are also targets of the
ROS produced by pro-oxidative factors such as Cu overload
or increased levels of NCBC.
Among the mitochondrial lipids directly affected by
ROS overproduction, cardiolipin (CL) is one of the most
deeply involved in both synapses and neuronal loss [31].
CL is linked to the endogenous proapoptotic cascade that
eventually leads to the integration of the apoptosome and the
subsequent activation of the effector caspase system [28–31].
Moreover, CL is involved in the regulation of the bioenergetic
process and in the integrity of mitochondrial membranes.
Peroxidation of CL directly affects the biochemical functions
that depend on the inner and outermitochondrialmembrane
composition and structure. Experimental evidence clearly
indicates that this lipid represents the most important target
of ROS attack [30].
In summary, there is conclusive evidence linking ROS
hyperproduction with mitochondrial dysfunction. Oxidative
stress is also directly involved in neurodegeneration and
Cu overload in association with cholesterol apparently acts
as a synergistic risk factor in the etiology of neurological
disorders. All the foregoing evidence suggests the need for
more in-depth study of this phenomenon. In view of the
absence of conclusive studies on the biochemical effects
of the Cu + Cho (CuCho) association on mitochondrial-
associated dysfunction, especially in relation to those aspects
involved in programmed cell death, we aimed to investigate
the effects of CuCho on mitochondria isolated from cortex
and hippocampus of Wistar rats and explore (i) the Cho/Pi
ratio and steady-state fluorescence anisotropy of the outer
and inner mitochondrial membranes in order to assess their
fluidities; (ii) mitochondrial membrane integrity by means
of a probe that measures trans-membrane potential; (iii)
the concentration of the main mitochondrial antioxidant
glutathione; (iv) the concentration of the key mitochondrial
phospholipid, cardiolipin, and the possible pro-oxidative
damage it causes; (v) the activity of the apoptotic pathway
depending on mitochondrial membrane integrity (caspase-
3 and the Bax/Bcl-2 ratio); and (vi) the concentration of 𝛽-
amyloid (A𝛽) in the two brain zones and in peripheral plasma
as a biomarker of a proneurodegenerative effect.
2. Materials and Methods
2.1. Chemicals. All chemicals used were of analytical grade
and obtained from Sigma Chem. Co. (Buenos Aires,
Argentina or USA),Merck (Darmstadt, Germany), and Carlo
Erba (Milan, Italy).
2.2. Animals and Treatments. Certified pathogen-free male
Wistar rats were used. The rats were maintained at a con-
trolled temperature (25∘C) and relative humidity of 60%
with forced ventilation, under a normal photoperiod of
12 h darkness and 12 h light. The health of the animals
was monitored in accordance with the internationally rec-
ommended practices of the Institute of Laboratory Animal
Resources, Commission of Life Sciences, National Research
Council (ILAR). Solid food and drinkingwater were provided
ad libitum. The diets for the experiments were prepared in
our laboratory according to the recommendations for Wistar
rats [32]. All procedures for handling the animals followed
the NIH regulations [33]. The experimental protocol was
reviewed and approved by the Bioethics Committee of the
Faculty of Medical Sciences, UNLP (number 00382/11).
2.3. Experimental Protocols. Rats (21 days old)were randomly
assigned (ten animals per group) to the protocols detailed as
follows and treated for eight weeks (2months). Selecting very
young rats lets us discard any neurodegenerative (unknown)
event(s) associated to the age of the animal. By the way, this
approach may be extrapolated to humans that are exposed
to copper from the very beginning of their life. In addition,
in previous experiments (not shown), we noted that—at lest
during the first year of life—that we have no differences
in the response of the model as a function of the starting
age of treatment. The control group (C) was maintained
on lab-prepared pellets as recommended for normal growth
containing 7 ppm of Cu [34, 35]. The Cu-supplemented
experimental group (Cu) was fed on control pellets and tap
water supplemented with 3mg/L (or ppm) of Cu in the form
of ultrapure CuSO
4
(Merck, Darmstadt, Germany).TheCho-
supplemented group (Cho) was fed on pellets containing
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2% (W/W) of Cho (87% pure) (obtained from Saporiti SRL,
Buenos Aires, AR), and the Cu + Cho-supplemented group
(CuCho) was simultaneously treated with Cu in water +
Cho in food. Rats were monitored during the experimental
period to observe their behavior, quantify water and food
consumption, and determine their body weight gain. Total
Cu concentration in tap water supplemented with CuSO was
determined by means of atomic absorption methodology
and was 3.42 ± 0.21 ppm (means of all daily measurements
taken along the experimental period). Considering that each
animal imbibed between 4.9±0.4 and 15.0±1.1mLwater/day
(at the beginning and the end of the protocol, resp.), a max-
imum of 0.01 to 0.05mgCu/day was acquired from water (a
dose equivalent to 0.06 and 0.18mgCu/Kg live animal, resp.).
Linear regression curves and ANOVA test for Cu content in
food demonstrated that there were no significant variations
between the 6 preparations used for the experiments (7.22 ±
0.31 ppm or mgCu/Kg diet). Fe and Zn content (determined
by atomic absorption spectrometry) was the same in all
preparations (45.9 ± 0.8 and 66.6 ± 2.0 ppm, resp.). Ingestion
of solid food along the experiments varied from 11.6 ± 0.8
to 29.7 ± 2.8 g/rat, implying that the oral ingestion of Cu
was in the range from 0.08 to 0.21mgCu/day/rat (0.0032 to
0.0008mgCu/Kg live animal).
2.4. Sample Collection. At the end of the treatments,
animals were deeply anesthetized with ketamine (70mg/Kg)
and xylazine (5mg/Kg) applied intramuscularly and then
sacrificed by decapitation. Brainswere removed and dissected
into two zones: cortex and hippocampus, using the atlas of
Paxinos andWatson [36] as a guide for tissue dissection. Both
brain regions were washed, weighed, and homogenized using
a Tris/HCl buffer (10mMpH 7.4) with sucrose (70mM),
mannitol (230mM), ethylenediaminetetraacetic acid
(EDTA) (1Mm), and dithiothreitol (DTT) (1mM) (Buffer I).
Homogenates were centrifuged at 2∘C 700×g for 10min and
the supernatants recentrifuged at 8,000×g (10min/2∘C) to
obtain the cytoplasm fraction. Pure mitochondrial fractions
were isolated from the pellets of the previous centrifugation
by resuspending them in 3mL of buffer I and centrifuging
during 5min at 1,000×g (2∘C).Thepellets were discarded and
the supernatants re-centrifuged for 10min at 11,000×g (2∘C).
Finally, the final pellet (mitochondrial fraction) was resus-
pended in buffer II (buffer I with 0.015% mg pure albumin
(Sigma Chem. Co.; Buenos Aires, AR)). Cytosol fractions
were prepared by ultracentrifugation of the supernatants at
110,000×g for 1 h at 2∘C. During the sacrifice of the animals,
blood was also collected using heparin as anticoagulant
(1 IU/5mL) in ice-cold polypropylene tubes. The plasma
samples were immediately prepared by centrifugation in the
cold (4,000×g, 10min) and stored at −70∘C until analyzed.
2.5. Atomic Absorption Measurements. Aliquots of sample
were digested with a mixture of 4mL of HNO
3
(c) and
1mL HClO
4
(Aldrich or Sigma Chem. Co., Buenos Aires,
Argentina) by heating at 120∘C for 60min in a mineralization
block [37]. The digests were cooled, diluted with ultrapure
water (18mΩ cm, Carlo Erba, Milan, Italy), and ultrafiltered
with a 0.22𝜇m Millipore membrane (Milli-Q Purification
System, fromMillipore, CA, USA). Ultrafiltered dissolutions
were directly aspirated into the flame of a PerkinElmer 1100
B Spectrophotometer equipped with a Perkin-Elmer cathode
lamp (Perkin-Elmer Corp., Norwalk, CT, USA) at a spectral
width of 1 nm. Standard solutions of 100 ppm Zn and Fe
from HCR Inc. (QuimiNet, Buenos Aires, AR) were used.
Cu determinations were calibrated with a standard solu-
tion (200 ppm) of Cu(NO
3
)
2
in HNO
3
0.5N (Titrisol from
Merck Co., Darmstadt, Germany). All measurements were
carried out in peak height mode (324.7 nm line). The intra-
[(SD/x) ⋅ 100] and inter-[(ΔSD/Δx) ⋅ 100] assay coefficients
of variation were 15.5 and 6.0%, respectively. We routinely
obtained a similar equation for the calibration curve (IR =
55 ⋅ 10−5 + 0.048 [Cu, mg/L]), and the statistical analyses
demonstrated a correlation coefficient always between 0.95
and 0.99. In addition, we explored the so-called matrix
effects that might have modified the slopes of the standard
regressions. In spiked samples, the obtained values varying
from 48 to 60 ⋅ 10−5 were very similar to those of Cu standard
solutions, indicating that the matrix effect was considered
nonsignificant or was negligible. The mean for recovery and
RSD for spiked samples was 99.7% and 3.3%, respectively,
and the detection limit was 0.09mg/L. In order to verify the
accuracy of the method, we explored the influence of time
after dilution, temperature of acid digestion, and concentra-
tion of HNO
3
/HClO
4
following the suggestions of Terre´s-
Martos et al. [38]. We also checked our results with biological
samples (plasma and homogenates) against a SeronormTrace
Elements Serum (from Sero Labs, Billingstad, Norway) and
found no significant differences between the obtained and the
declared (certified) concentrations.
2.6. Ceruloplasmin (CP) Levels and Nonceruloplasmin-Bound
Copper (NCBC). Samples were analyzed by the enzyme con-
version of p-phenylenediamine into a blue-colored product
[39]whichwas thenmeasured at 550 nm.Reaction proceeded
at 37∘C in buffer glacial acetic/sodium acetate (50mM, pH
5.5) directly into flat-bottomed plates, using a Microplate
Reader SpectraMax M2/m2e model from Molecular Devices
Analytical Technologies (Sunnyvale, CA, USA) for 3min.
Intra- and interassay coefficients of variation were 8.3 and
4.4%, respectively. CP concentrations were calculated by
comparison with the reaction rate of pure CP standard
(Sigma Chem. Co., Buenos Aires, Argentina). Using the Cu
and CP data we calculated the non-CP-bound Cu (NCBC, or
so-called free Cu) as described by Brewer [19] by subtracting
the amount of Cu bound to each mg of CP from data of total
Cu. This parameter can be easily expressed in percentages
using the formula (([Cu] − 47.2 × [CP]) × 100/[Cu]) where
Cu is in 𝜇mol/L and CP in g/L [40].
2.7. Lipid Analysis. Total lipids were extracted by the
method of Folch et al. [41]. An aliquot of each Folch
extract was evaporated and the residue dissolved in 50mM
sodium phosphate buffer (pH 7.4) containing digitonin
1%. Aliquots of this solution were taken to enzymatically
measure cholesterol (Cho) and phospholipids (PL) using
commercial kits from Wienner Lab (Rosario, Argentina).
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To determine the mitochondrial cardiolipin (CL) content,
samples were separated by high-performance thin-layer
chromatography (HPTLC) on precoated silica gel plates (10 ×
20 cm) with concentration zone from Whatman Schleicher
and Schuell (Maidstone, England). The mobile phase was
chloroform :methanol : ammonium hydroxide (65 : 25 : 4; by
volume). Spots were localized using iodine vapor on a
lateral lane spotted with authentic standards of CL, mono-
and dilyso-CL, and other reference phospholipids (Avanti
Polar Lipids, Ontario, Canada). The rest of the plate was
covered with a glass to avoid possible spontaneous oxidation.
The CL and lyso-CL zones were scraped off the plates
and eluted from the silica with “inverse” Folch extraction
(chloroform :methanol; 1 : 2). After evaporation under nitro-
gen at room temperature, the selected zones were dissolved
in 200𝜇L of Folch solvent mixture. The total amount of
CL and lyso-CL was quantified by means of phosphorous
measurement using the method of Chen et al. [42].
2.8. Mitochondrial Membrane Integrity. The mitochondrial
membrane potential (Δ𝜓) was measured by estimating the
integrity of the mitochondrial membrane using the iso-
lated mitochondrial staining kit from Sigma-Aldrich, Inc.
(Buenos Aires, AR). This kit is based on the uptake of
the lipophilic cationic probe 5,5󸀠,6,6󸀠-tetrachloro-1,1󸀠,3,3󸀠-
tetraethyl-benzimidazolcarbocyanine iodide dye (JC-1) into
the mitochondrial matrix which directly depends on the Δ𝜓.
In healthy cells, the dye concentrates in the matrix, where
it forms bright red fluorescent agglomerates. Uptake by the
mitochondria of JC-1 can be utilized as an effective distinction
between apoptotic and healthy cells. Any event that dissipates
the Δ𝜓 prevents the accumulation of the JC-1 dye in the
mitochondria, and the dye is thus dispersed in the cytoplasm,
leading to a shift from red (JC-1 agglomerated) to green
fluorescence (JC-1 monomers). To measure the samples, we
used a PerkinElmer LS 55 Fluorescence Spectrometer, set at
525 nm excitation wavelength and 590 nm emission.
2.9. Steady-State Fluorescence Anisotropy of DPH and TMA-
DPH. Submitochondrial fractions (inner and outer mem-
branes) were obtained following the method described by
Fraser and Zammit [43] with the modifications of Pellon-
Maison et al. [44]. Prior to membrane fluidity assays, total
protein concentration was determined in each suspension
and adjusted to approximately 300 𝜇g protein/mL using
5mM TRIS/HCL buffer pH 7.40. Membrane fluidity was
determined by the fluorescence anisotropy (or polarization)
technique using two fluorescent probes: 1,6-diphenyl-1,3,5-
hexatriene (DPH; Sigma-Aldrich, St. Louis, MO) and 1-[4-
(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene (TMA-
DPH; Molecular Probes, Eugene, OR). TMA-DPH was used
to monitor fluidity near the surface of the cell membrane.
The polar region of this probe is anchored at the lipid-
water interface and the hydrocarbon moiety enters the lipid
part of the membrane. The length of the hydrophobic part
of the TMA-DPH molecule is approximately equivalent to
that of a plasma membrane [45]. DPH is incorporated into
the hydrophobic regions of the lipid bilayer [46]. DPH or
TMA-DPH anisotropy is inversely correlatedwithmembrane
fluidity [47]. Anisotropy measurements were performed as
previously described [48], with slight modifications. Briefly,
membranes were vigorously homogenized using a vortex
vibrator for 1min and subjected to mild sonication in a
Branson sonifier 450 (Branson Ultrasonic SA, CA, USA) (set
at 40% output) following a 3min incubation period on ice.
The sonication cycle was controlled by the turbidity of the
suspension as evaluated at 600 nm and was interrupted when
an absorbance value of 0.2 or less was reached.This procedure
does not interfere with the transition of lipid bilayers but
disperses aggregates, facilitating fluorescence readings and
decreasing light scattering [49]. The samples for the DPH
and TMA-DPH assays (3mL) contained 5mM Tris–HCl
buffer pH 7.4, 60 𝜇g of protein from diluted suspensions,
and 50 𝜇M MDPH in tetrahydrofuran or 25 𝜇M TMA-DPH
in dimethylformamide and were incubated for 45min at
37∘C.The steady-state anisotropywasmeasured in aHe𝜆10S𝛽
spectrofluorophotometer (Thermoelectron Corp., Sydney,
Australia) equipped with a thermostated cell holder. The
sample’s temperature was checked to an accuracy of ±0.1∘C
using a thermistor thermometer. Excitation and emission
were set at 357/435 nm and 358/428 nm for DPH and TMA-
DPH (resp.) using 5 nm excitation and emission slits. Samples
were illuminated with linear (vertically, V, or horizontally, ℎ)
polarized monochromatic light and the fluorescence intensi-
ties emitted (𝐼, in arbitrary units) parallel or perpendicular
to the direction of the excitation beam were recorded. Blank
samples without the addition of the probe(s) were also
measured to estimate unspecific light that might reach the
detector. The fluorescence anisotropy of the probes (𝑋) was
calculated as 𝑟(𝑋) = [𝐼VV−𝐼Vℎ×𝐺] = [𝐼VV+2𝐼Vℎ×𝐺], where
𝐼VV and 𝐼Vℎ are the intensities of the fluorescence emitted,
respectively, parallel and perpendicular to the direction of the
vertically polarized excitation light; G is the correction factor
(𝐺 = 𝐼ℎV/𝐼ℎℎ) for the optical system given by the ratio of the
vertically to the horizontally polarized emission components
when the excitation light is polarized in the horizontal
direction; and𝑋 represents TMA-DPHorDPH.According to
Shinitzky and Barenholz [50], fluorescence anisotropy values
are inversely proportional to cell membrane fluidity. Thus,
a high degree of fluorescence anisotropy represents a high
structural order or low cell membrane fluidity.
2.10.Mitochondrial Reduced (GSH) andOxidized (GSSG)Glu-
tathione Content. Total glutathione was determined by the
glutathione reductase/dithionitrobenzoic (DTNB) method
that can measure both GSH and GSSG [51]. Mitochondrial
GSH (mGSH) were calculated by subtracting GSSG from
the total glutathione content (GSH + GSSG). For this reason
samples were run in the presence and absence of 2mM
divinylpyridine.
2.11. Programmed Cell Death Biomarkers
2.11.1. Caspase-3Activity. Caspase-3 activitywasmeasured by
a colorimetric assay kit (CASP-3-C), based on the hydrolysis
of the synthetic peptide substrate acetyl-Asp-Glu-Val-Asp-p-
nitroaniline (Ac-DEVD-pNA) by caspase-3 (Sigma Chem.
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Co., Buenos Aires, Argentina). The resulting p-nitroaniline
(p-NA) released was monitored at 405 nm. Each assay was
run in parallel with inhibitor-treated cell lysate (to measure
the nonspecific hydrolysis of the substrate) and caspase-
3 positive control (using commercial caspase-3, 5mg/mL
provided by the kit manufacturer). A calibration curve using
a standard solution of p-nitroaniline (p-NA) was also run for
each assay to calculate the activity of the protease expressed
as 𝜇mol p-NA released/min ⋅mL of sample.
2.11.2. Bax/Bcl-2 Ratio. Western blot assays of Bax and Bcl-2
were performed to calculate the Bax/Bcl-2 ratio. Equal quan-
tities (30 𝜇g protein per lane) of total protein were separated
by SDS-PAGE (15% gels) under reducing conditions and a
Miniprotean VI unit (Bio-Rad, CA, USA). The proteins were
then electrophoretically transferred to PVDF membranes
(IPVH00010 Immobilon, Millipore, USA). The membranes
were blocked with 5% skimmed milk and incubated with
anti-Bcl-2 and anti-Bax antibodies, respectively (1 : 1000; sc-
492 rabbit polyclonal and sc-493 rabbit polyclonal from Santa
Cruz CA, USA, resp.), at 4∘C overnight. This was followed
by incubation with goat anti-rabbit secondary antibody con-
jugated with horseradish peroxidase (1 : 20.000; Santa Cruz,
CA, USA). Photographs were taken using the Molecular
Imager Gel Doc XR and ChemiDoc XRS systems (Bio-Rad)
and the optical densities of the bands were quantified.
2.12. Beta-Amyloid Peptides (1–40) and (1–42). Beta-amyloid
peptides (A𝛽) (1–40) and (1–42) were measured using the
Human/Rat𝛽Amyloid-40 ELISAkitWako II and theHuman
Amyloid-42 ELISA kit Wako High-sensitive, respectively.
Before the assay the samples were centrifuged (2∘C) at
5000×g for 15min and the supernatants diluted 1 : 1 with
the buffer provided by the manufacturer. Results for plasma
were expressed in pmoles/L and for brain tissues in pmol/mg
protein. The A𝛽(1–42)/(1–40) ratios were calculated from
each individual pair of data.
2.13. Biomarkers of Cardiolipin Peroxidation
2.13.1. Authentic Lipoperoxides. Lipoperoxides (LPOO) in
cardiolipin extracts (CL) were determined according to the
method of Nourooz-Zadeh et al. [52]. Results were expressed
as 𝜇moles LPOO/𝜇moles CL (for calculation we used an
extinction coefficient of 4.60 (10−4) ⋅mol−1 ⋅ cm−1 at 560 nm).
2.13.2. Conjugated Dienes. The spectrophotometric detec-
tion of conjugated dienes was performed according to the
methodology described by Recknagel and Glende [53]. The
spectral register between 300 and 220 nm was obtained and
subtracted from a blank spectrum of pure cyclohexane.
Conjugated dienes show a typical absorption band in the
range of 230–240 nm. The results were expressed as relative
units of optical density (UDO)/mg mitochondrial CL.
2.14. Statistical Analysis. All values represent the mean of
10 rats assayed in triplicate expressed as mean ± standard
deviation (SD). Data were analyzed by ANOVA plus the
Tukey test with the aid of SPSS 11.0.1 software (SPSS Inc.,
Chicago, IL). To analyze the bands obtained by western blot,
we used the Image J software for image processing (National
Institute of Health, USA). Results were also plotted and
analyzed using Sigma Scientific Graphing Software (version
11.0) from Sigma Chem. Co. (St. Louis, MO). The statistical
significance (𝑃 ≤ 0.01) of differences is indicated by
superscript letters (values with distinct letters are statistically
different between them).
3. Results
Growth parameters (final weight gain, rate of body weight,
food efficiency ratio, etc.) showed no significant differences
between the experimental groups (data not shown). Also,
water intake among the experimental groups was essentially
identical, which is a reason to assume that the rats did not
note any difference in the palatability of the supplemented
water compared with the nonsupplemented one. The same
happened with solid food.
3.1. Copper Content in Mitochondrial Suspensions. Atomic
absorption measurements demonstrated that the total Cu
content in digested mitochondrial suspensions did not differ
significantly among the experimental groups. However,mean
values for cortex were higher than those for hippocampus
(5.9±0.4 versus 4.0±0.2 g/mgmitochondrial proteins, resp.).
3.2. Nonceruloplasmin-Bound Copper (NCBC) and Cerulo-
plasmin (CP) Concentrations. Figure 1(a) shows the concen-
tration of free Cu (expressed as NCBC) in plasma and
in both brain zones analyzed. Plasma and hippocampus
showed significant increases after Cu and CuCho treatments
compared to the control group. In cortex, we observed no
significant differences.
We also analyzedCP concentration in plasma, cortex, and
hippocampus after the experimental diets (Figure 1(b)). CP
increased significantly after Cu and CuCho supplementation
in plasma and in both brain zones. Cortex and hippocampus
from rats fed on the CuCho diet also showed significant
increases with respect to the Cu treatment alone.
3.3. Effect of Diets on Mitochondrial Membrane Physicochem-
ical Properties. Figure 2 shows the ratio between Cho and
total phospholipids (measured as total inorganic phosphate
or Pi) in cortex and hippocampus. In both brain zones,
Cu treatment produced a significant increase in this ratio.
Supplementation with Cho and with Cu + Cho (CuCho) also
produced significant increases in the Cho/Pi ratio compared
to the control or Cu treatment alone.
The mitochondrial membrane potential was estimated
by fluorimetric determination of the degree of aggregation
of the JC-1 dye in mitochondrial suspensions from brain
cortex and hippocampus (Figure 3). Supplementation with
Cu alone produced no significant changes in hippocampus
and a discrete although significant increase in the membrane
permeability in cortex. In both brain zones cholesterol sup-
plementation also produced a clear loss of integritywhichwas
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Figure 1: Free Cu (NCBC) (a) and ceruloplasmin (CP) (b) levels in
brain cortex and hippocampus homogenates (ng/mg total protein).
Treatments are indicated with different colors, control (white bars),
Cu (black bars), Cho (gray bars), and CuCho (dark gray bars).
Samples were analyzed as indicated in Sections 2.5 and 2.6. Results
are expressed as mean of 10 rats assayed in triplicate ± standard
deviation (SD). Significant differences among the experimental
groups are indicated with superscript letters (values with distinct
letters are significantly different between them, 𝑃 < 0.01).
more pronounced when the lipid was associated with Cu in
drinking water (especially in hippocampus).
3.4. Glutathione Content and Biomarkers of Lipid Peroxi-
dation. Cho and CuCho treatments produced a significant
decrease in total mitochondrial glutathione (GSH + GSSG)
in both brain zones compared to the control data and to
supplementation with Cu alone (Figure 4). Reductions were
more evident in hippocampus than in cortex. Addition of
inorganic Cu to drinking water did not produce significant
changes with respect to the control group.
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Figure 2: Cholesterol (Cho) and total phospholipids (measured
as total inorganic phosphate or Pi) ratio (Cho/Pi) in brain cortex
and hippocampus homogenates (ng/mg total protein). Samples
were analyzed as indicated in Section 2.7. Treatments are indicated
with different colors, control (white bars), Cu (black bars), Cho
(gray bars), and CuCho (dark gray bars). Results are expressed as
mean of 10 rats assayed in triplicate ± standard deviation (SD).
Significant differences among the experimental groups are indicated
with superscript letters (values with distinct letters are significantly
different between them, 𝑃 < 0.01).
Figure 5 shows the concentration of two products of CL
fatty acids oxidation, lipoperoxides (LPOO), and conjugated
dienes (Figures 5(a) and 5(b), resp.). Significant increases
in LPOO were observed after Cu addition in hippocampus
and in cortex with respect to control data. Cho treatments
produced a significant decrease in this biomarker in hip-
pocampus. A very significant increase was observed for the
CuCho treatment with respect to supplementation with Cu
or Cho alone for both brain zones. After Cu and CuCho
treatments, the amount of conjugated dienes was also higher
compared to control data in hippocampus and in cortex.
3.5. Cardiolipin (CL) and Lyso-Cardiolipin (LCL) Content
in Mitochondrial Suspensions. Figure 6(a) shows the total
concentration of mitochondrial CL in 𝜇mol of inorganic
phosphate (Pi)/mg protein. After Cu treatment, CL con-
tent decreased in both brain zones analyzed. The Cho-
supplemented diet increased CL in both cortex and hip-
pocampus, whereas cosupplementation with Cu and Cho
produced no significant changes with respect to the control
diet. Figure 6(b) shows the levels of lyso-CL (LCL) after
dietary treatments. All diets induced significant increases in
LCL concentrations in hippocampus and cortex compared to
control data; however, the higher increases were observed for
the groups treated with Cu (alone or in combination with
Cho).
3.6. Mitochondrial Membrane Apparent Microviscosities. Iso-
lated outer and inner mitochondrial membranes were exam-
ined for their apparentmicroviscocities using two fluorescent
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Figure 3: Mitochondrial membrane potential in brain cortex and
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gray bars). Sampleswere analyzed as indicated in Section 2.8. Results
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Table 1: Caspase-3 activity in brain cortex and hippocampus from
the experimental diets.
Diets Cortex Hippocampus
C 2.1 ± 0.1 1.4 ± 0.1
Cu 2.3 ± 0.2 1.5 ± 0.1
Cho 2.0 ± 0.1 1.4 ± 0.3
CuCho 2.4 ± 0.1 1.7 ± 0.1
Results were obtained as described in Section 2.11.1. They were expressed as
the mean of 10 independent determinations ± SD. There are no statistical
differences ascribed to the experimental diet.
probes (DPH or TMA-DPH) that explore different zones of
the lipid bilayer. Figures 7 (cortex) and 8 (hippocampus)
show the values of the anisotropies which are inversely
correlated with (outer and inner) membrane fluidities. In
both brain regions and with both probes tested, we observed
decreased fluidities and increased fluorescence anisotropies
produced by cholesterol supplementation either alone or in
combination with Cu.
3.7. Programmed Cell Death Biomarkers. Despite the damage
observed in the integrity of the inner mitochondrial mem-
brane (JC-1 measurements), we did not detect any significant
increase in Cyt C in cytosol fractions with the sole exception
of a slight—although significant—increase in brain cortex
from rats simultaneously treated with Cu and Cho (data not
shown). In agreement with this finding, caspase-3 activity
was not significantly modified in any experimental group
(Table 1) nor was there any significant alteration in the
Bax/Bcl2 ratio (Figure 9).
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Figure 4: Mitochondrial glutathione (mGSH) content in brain
cortex and hippocampus (ng/mg total protein). Treatments are
indicated with different colors, control (white bars), Cu (black
bars), Cho (gray bars), and CuCho (dark gray bars). Samples
were analyzed as indicated in Section 2.10. Results are expressed
as mean of 10 rats assayed in triplicate ± standard deviation (SD).
Significant differences among the experimental groups are indicated
with superscript letters (values with distinct letters are significantly
different between them, 𝑃 < 0.01).
Table 2: Ratio A𝛽(1–42)/(1–40) in plasma and brain cortex and
hippocampus after the experimental diets.
Diets Plasma Brain
Cortex Hippocampus
C 6.5 ± 1.0a 7.3 ± 0.9a 6.3 ± 0.7a
Cu 6.8 ± 0.8a 9.2 ± 0.5b 6.6 ± 0.4a
Cho 7.1 ± 1.1a 9.2 ± 0.6b 9.6 ± 0.5b
CuCho 8.5 ± 0.8a 10.9 ± 0.5c 9.3 ± 0.6b
Data were obtained as described in Section 2.12. They correspond to the
mean of 10 individual determinations assayed in triplicate ± SD. Differences
statistically significant among the different diets are indicated with distinct
superscript letters.
3.8. Biomarker of Neurodegeneration. Table 2 shows the
A𝛽(1–42)/(1–40) ratio in plasma and in cortex and hippocam-
pus homogenates as a biomarker of neurodegeneration.
Cu or Cho treatments produced a significant increase in
this biomarker in brain cortex and the CuCho association
produced an even more significant increase. Cho supple-
mentation increased the ratio in hippocampus with a value
indistinguishable from that observed for the simultaneous
treatment with Cu and Cho.These changes were not reflected
in peripheral plasma.
4. Discussion
Inappropriate dietary copper and cholesterol intakes are
implicated in the development of Alzheimer’s disease. This
study follows previous experimental evidence reporting
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Figure 5: Levels of lipoperoxides (LPOO) (a) and conjugated dienes
(b) in mitochondrial fractions from brain cortex and hippocampus.
Results are expressed as 𝜇moles of LPOO/𝜇Moles of Pi in CL, or
UDO/mg protein, respectively. Treatments are indicated with dif-
ferent colors, control (white bars), Cu (black bars), Cho (gray bars),
and CuCho (dark gray bars). Samples were analyzed as indicated in
Sections 2.13.1 and 2.13.2. Results are the mean of 10 rats assayed in
triplicate ± standard deviation (SD). Significant differences among
data are indicatedwith superscript letters (valueswith distinct letters
are significantly different between them, 𝑃 < 0.01).
the impact of dietary Cu and Cho manipulations as pro-
neurodegenerative cause in animal models.
The impact of elevated inorganic Cu, Cho, or a combina-
tion of both in the diet (for 2 months) significantly modifies
themitochondrial function. Results suggest that these dietary
supplements are able to increase oxidative damage in brain
cortex and hippocampus (with a substantial increment of
the lipoperoxides and conjugated dienes in the cardiolipin
subfraction), increase the proportion Cho/phospholipids,
and consequently decrease the concentration of mGSH,
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Figure 6: Cardiolipin (CL) (a) and lyso-CL (LCL) (b) levels inmito-
chondrial fractions from brain cortex and hippocampus (𝜇moles of
Pi/mg total protein). Treatments are indicated with different colors,
control (white bars), Cu (black bars), Cho (gray bars), and CuCho
(dark gray bars). Samples were analyzed as indicated in Section 2.7.
Results are the mean of 10 rats assayed in triplicate ± standard
deviation (SD). Significant differences among the experimental
groups are indicated with superscript letters (values with distinct
letters are significantly different between them, 𝑃 < 0.01).
decrease the membrane potential, modify the proportion of
cardiolipin and lyso-derivatives, alter inner and outer mito-
chondrial membrane fluidities, and increase A𝛽(1–42)/(1–40)
ratio.
It is well known that the metabolism of Cu in humans
is under strictly regulated control. The usual concentration
of total Cu in human plasma (as determined by us and
other groups) is in the range of 0.3 to 2.1mg/L for intakes
of 1.4 to 2.0mgCu/day [16]. However, the amount of Cu not
bound to ceruloplasmin (NCBC) is very low and has been
associated with some of the features of neurodegenerative
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Figure 7:Mitochondrial outer (a) and inner (b)membrane fluidities
(fluorescence anisotropy) in suspension isolated from brain cortex.
Treatments are indicated with different colors, control (white bars),
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Samples were analyzed as indicated in Section 2.9. Results are
expressed as the mean ± standard deviation (SD) of 10 rats.
Significant differences among the experimental groups are indicated
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different between them, 𝑃 < 0.01).
disorders such as AD [16, 17]. Cholesterol was also associated
with the etiology or increased risk of developing AD [54–57].
Thus, our experimental system was designed to investigate
the possible concurrence of these two factors in promoting
neurodegeneration, with a focus on their role in mito-
chondrial function. Mitochondrial dysfunction due to ROS
overproduction and/or the alteration of the physicochemical
properties of their membranes (mainly lipid composition)
was reported to be the main factor in the advance of AD,
featuring early on in the progression of the disease [25–27].
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Figure 8:Mitochondrial outer (a) and inner (b)membrane fluidities
(fluorescence anisotropy) in suspension isolated from brain hip-
pocampus. Treatments are indicated with different colors, control
(white bars), Cu (black bars), Cho (gray bars), andCuCho (dark gray
bars). Samples were analyzed as indicated in Section 2.9. Results
are expressed as the mean ± standard deviation (SD) of 10 rats.
Significant differences among the experimental groups are indicated
with superscript letters (values with distinct letters are significantly
different between them, 𝑃 < 0.01).
In discussing the validity and/or limitations of our exper-
imental system, it is necessary to consider the level of the
supplementation with Cu and Cho and the characteristics
of the metabolism of these two dietary supplements. With
respect to Cu overload using oral administration, our exper-
imental conditions were based on previous work [23, 24] and
resemble the Cu levels commonly found as a consequence of
involuntary exposure through air, food, and water pollution
[8, 58–60], ingestion of dietary mineral supplements, and
in professionals engaged in agrochemical activities [9–12] or
female users of Cu-based intrauterine devices [13, 14]. Studies
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Samples were analyzed as indicated in Section 2.11.1. Results are
expressed as the mean ± standard deviation (SD) of 10 rats. There
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performed in rats demonstrated that Cu metabolism and
homeostasis are essentially identical to those in humans [61].
Similarly, oral Cho supplementation was selected on the basis
of previous experiments by other researchers [22–24], and
the plasma Cho concentration represents an approximately
30% increase over themediumvalues obtained for the control
group. This increase is frequently observed in humans with
dyslipemia [62]. We chose a treatment duration equivalent to
approximately 6 years in human terms and therefore assume
that the experimental exposure conditions can reasonably be
extrapolated to human populations. The known differences
between the metabolism of lipoproteins in rats as opposed to
humans could be considered a limitation to this assumption,
but this can be taken into account as in the case of other
experimental models (rabbits or hamsters, e.g.). It is impor-
tant to recall that rats are quite unique in terms of their sterol
metabolism, since in other species studied previously (rabbit,
guinea pig, hamster, and squirrel monkey) the liver displays
a secondary function, whereas extrahepatic tissues play a
quantitatively major role in whole animal sterol biosynthesis
and metabolism [63].
Cu supplementation in the trace amounts used here did
not substantiallymodify the concentration of themetal inside
the mitochondria isolated from cortex or hippocampus.
However, after two months of treatment, we observed an
increase in CP concentration in both brain zones in those
experimental groups that received Cu. We attribute this
increase mainly to a response to the proinflammatory condi-
tion induced by the Cu-induced oxidative stress as described
in our previous work [64]. We were unable to measure
the NCBC inside the purified mitochondrial fraction mainly
due to the lack of CP or to the presence of this protein in
amounts beyond detection by our method of measurement.
However, in plasma and in whole homogenates we found that
NCBC was increased by Cu administration even in the small
amounts used here. Concomitantly, theCP concentrationwas
also higher in all samples except cortex, which probably has a
strong homeostatic system to control Cu levels. In agreement
with previous findings, Das et al. [65] reported that increases
of free Cu (NCBC) stimulate the expression of CP through
the activation of AP-1.
Experimental diets also produced significant changes
in the lipid composition of mitochondrial fractions. Cu
supplementation increased the Cho/phospholipid ratio in the
cortex and hippocampus of Wistar rats. This increase was
even more pronounced after Cho or CuCho addition. These
changes must obviously be associated with the modification
of themetabolism (uptake, biosynthesis, and/or degradation)
of both subtypes of lipids. The elucidation of these effects
remains to be investigated in detail, opening a new avenue of
research of potential importance in the search for therapeutic
targets in neurodegenerative processes. As a consequence of
the aforementioned changes, we observed significant modifi-
cations in the physicochemical properties of mitochondrial
membranes. The transmembrane potential was altered in
Cu- and Cu + Cho-treated rats. Furthermore, the apparent
microviscocity of both mitochondrial membranes (outer
and inner) was profoundly altered by Cho and CuCho
treatments. Generalized and extensive damage in the form
of increased permeability (JC-1) and rigidization was mainly
demonstrated by the use of two probes with substantially
different capacities of lipid bilayer exploration (DPH and
TMA-DPH).These findings are in agreement with previously
reported data associating the loss of membrane fluidity with
an increase in the Cho/Pi ratio [66]. These changes are of
relevance from the physiological point of view. It is known
that many membrane protein functions including carriers,
enzymes, and receptors, among others, can be modulated
by the microenvironment of the membrane where they are
embedded [66]. Since ROS overproduction has a key role in
AD and other neurodegenerative illnesses [67, 68], we will
focus on the possible consequences of changes in membrane
properties on mitochondrial redox homeostasis and the
possible activation of programmed cell death signals.
Mitochondrial glutathione (mGSH) is considered the
key antioxidant for mitochondrial functioning and survival.
It is the main line of defense for the maintenance of the
appropriate mitochondrial redox environment by prevent-
ing or repairing oxidative modifications that could lead to
mitochondrial dysfunction and cell death.The importance of
mGSH lies not only in its abundance but also in its extreme
versatility to counteract hydrogen peroxide, lipid hydroper-
oxides, or xenobiotics, mainly as a cofactor of enzymes
such as glutathione peroxidase or glutathione-S-transferase.
Many cell-inducing stimuli, such as excess NCBC or other
transition metals that induce oxidative stress, reduce the
levels of mGSH and sensitize the mitochondria to additional
insults (e.g., excess cholesterol in the composition of their
biomembranes) [66]. Interestingly, the transport of GSH into
the mitochondria is critically dependent on the maintenance
of physiologically regulatedmembrane parameters, especially
the Cho/Pi ratio and the apparent microviscocity of the inner
mitochondrial membrane [66–70]. The dicarboxylate carrier
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Figure 10: Lineal correlation coefficients for the relationship between mGSH and Cho/Pi ratio in cortex (a) and hippocampus (b) grouped
according to two groups of data independently of Cu supplementation, one for rats that did not receive cholesterol (−Cho) and the other for
animals fed on diets supplemented with Cho (+Cho). The values of the 𝑟2 for each curve adjustment appear in parenthesis.
and the 2-oxoglutarate carrier have been shown to function
as GSH transporters highly sensitive to the physiochemical
state of mitochondrial membranes [69].The activities of both
GSH carriers were inhibited for a decrease in the membrane
fluidity. In agreement with these facts, we not only observed
a decrease in mGSH in the Cho-supplemented rats but also a
strong negative correlation between mGSH and the Cho/Pi
ratio in mitochondrial membranes (Figure 10). Cu supple-
mentation also produced an increase in the Cho/Pi ratio,
though not sufficiently to significantly modify the membrane
fluidity, leaving it unable to modify the mGSH levels.
Depletion of the main antioxidant defense system in
mitochondria is directly linked to increased lipid peroxida-
tion. A pro-oxidative environment clearly promotes the oxi-
dation of CL and also stimulates its regeneration or remodel-
ing activity by increasing the intermediary metabolites, lyso-
CL (mono- and dilyso-CL in cortex and hippocampus). In
line with this, we found higher LPOO and conjugated diene
production in isolated CL subfractions after Cu addition
that was even more pronounced after cosupplementation
with Cho (CuCho). Peroxidized CL decreases the pool of
CL available in mitochondria, thus preventing the formation
of the transition pore and the subsequent leakage of Cyt C
to the cytosol. Moreover, oxidized CL was able to produce
mitochondrial dysfunction, preventing electron transport
through the protein complexes [28, 68]. Our finding of lower
mitochondrial CL content after Cu treatment in both brains
zones is in agreement with previous observations of Yurkova
et al. [71]. They reported that Cu ions possess the ability
to fragment CL with the subsequent formation of phospha-
tidic acid and phosphatidyl hydroxyacetone in mitochondria
from a mouse model of Wilson’s disease. Interestingly, Cho
supplementation produced an increase in CL levels prob-
ably through an ROS-dependent overstimulation of acyl-
transferase-1 activity [72].The fact that no significant changes
with respect to control rats were observed under CuCho
treatment could be explained in terms of a compensatory
mechanism to counteract the opposite effects produced byCu
and Cho supplementations.
Cho enrichment of mitochondrial membranes has other
important consequences. Alterations in the physical proper-
ties of mitochondrial membranes, such as those revealed by
the response to DPH and TMA-DPH probes, could modify
mitochondrial dynamics, which are critical for the main-
tenance of mitochondrial integrity and functions including
energy production, ROS generation and apoptosis regulation
[26–31]. Modifications in mitochondrial dynamics lead to
structural changes in cristae formation and the assembly of
electron transport complexes, compromising bioenergetics
and causing calcium dyshomeostasis, increased oxidative
stress (consumption ofmGSH),mitochondrial DNAdamage,
and synaptic dysfunction [28–30].
We have mentioned that the pro-oxidative condition
induces CL peroxidation and in consequence diminishes CL’s
ability join to proteins like Cyt C. Montero et al. [73] and
Eckmann et al. [74] emphasized that even though only 15%
of the Cyt C is strongly bound to CL, the oxidation of minor
amounts of this phospholipid could trigger the mobilization
of the Cyt C from the mitochondrial inner membrane to
the intermembrane space and then to the cytosol. However,
we found no significant changes in Cyt C release to the
cytoplasm after any treatments, except in the case of CuCho
addition to the cortex.There were also no significant changes
in the Bax/BcL-2 ratio and in caspase-3 activity, indicating
that the intrinsic apoptotic pathway was still not significantly
activated.The pro-oxidative conditions likely induced by Cu,
together with the enrichment of cholesterol that reduces
mGSH levels, produce CL peroxidation; however, it appears
that the level of damage is insufficient to produce a signif-
icant stimulation of apoptosome formation and subsequent
activation of the caspase-3 pathway [73]. Our lab is now
studying the effect of a more prolonged time of exposure in
order to investigate the chronic effects of these experimental
treatments.
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Lu et al. [24] reported that Cu is associated with A𝛽
in senile plaques and that this complex can recruit Cho
molecules, oxidizing them and producing even more ROS.
Despite the clear activation of the proapoptotic cascade, we
found an increase in A𝛽 formation in the brain, a condition
which is a recognized biomarker of neurodegeneration.These
changes in cortex and hippocampus were not reflected in
peripheral plasma, most likely because the latter is less
sensitive or the duration of the treatment was not sufficient to
affect the proportion between A𝛽(1–42)/(1–40) in peripheral
plasma, or both. Oxidative stress induces A𝛽 accumulation
in mitochondrial membranes, causing structural and func-
tional damage. Amyloid-𝛽 interacts with the mitochondrial
protein A𝛽-binding alcohol dehydrogenase (ABAD) which
is upregulated in the temporal lobe of AD patients as well
as in A𝛽PP transgenic mice [28]. This complex prevents
the binding of nicotinamide adenine dinucleotide to ABAD,
thereby changing mitochondrial membrane permeability (as
we observed in our model) and reducing the activities of
respiratory enzymes triggering elevated ROS production
[28–30]. Increased A𝛽 production and A𝛽-ROS-dependent
formation are linked to other important issues such as
the inactivation of the presequence protease (PreP), one of
the most important proteins involved in A𝛽 degradation;
alteration of mitochondrial dynamics (previously discussed);
increased nitrosative stress; activation of cyclophilin D (an
integral part of the permeability transition pore or mPTP);
potentiation of synaptic failure; and cytoskeletal aberrations,
among others [26–31]. All these facts indicate the importance
of monitoring the level of A𝛽 production not only at the local
(SNC) but also at the systemic (peripheral plasma) level.
5. Conclusions
Our work demonstrates that dietary supplementation with
trace amounts of inorganic Cu in drinking water + Cho
supplementation in solid food causes oxidative stress in brain
cortex and hippocampus by depletion of mGSH in an inverse
Cho/Pi-dependent fashion; CL peroxidation and stimulation
of the remodeling route; major alterations in mitochondrial
membrane integrity and fluidity; and a higher A𝛽(1–42)/(1–
40) ratio as a biomarker of neurodegeneration.These changes
may be additive and could lead—under more prolonged
exposure—to activation of the proapoptotic cascade. On-
going research will shed further light on the real significance
of the present results and establish the intimate mechanisms
underlying the damage induced by these two very common
factors (Cu and Cho overload) with a view to defining
potential preventive strategies in human populations at risk.
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